Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology. in Leukemia / Leukemia. 2026 Sep;40(9):1961-1967. doi: 10.1038/s41375-026-03036-8. Epub 2026 Jul 7.

2026
AOU Alessandria

Tipo pubblicazione

Journal Article

Autori/Collaboratori (22)Vedi tutti...

Lippl J
Department of Medical Bioinformatics, University Medical Center Göttingen, Göttingen, Germany.
Reinke S
Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Koch K
Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

et alii...

Abstract

The clinical course of Mantle Cell Lymphoma (MCL) varies between individual patients. Early detection of risk is crucial to assign MCL patients to novel treatment strategies. Most of the established biomarkers of outcome require specifically trained pathologists or molecular analysis. Here we introduce MAIPI (MCL Artificial Intelligence Prognostic Index), a deep learning algorithm trained only on Hematoxylin and Eosin (H&E) images of diagnostic biopsies of n?=?428 MCL patients from clinical trials to assess prognosis. The capability of MAIPI to predict disease outcome was validated in an independent cohort of n?=?140 patients treated with immunochemotherapy with and without ibrutinib. MAIPI selects areas of interest by itself and provides prognostic information independent of the MCL International Prognostic Index (MIPI) and Ki67 and without the need of molecular testing or expert pathologists evaluation.

Accesso banca dati bibliografica

PMID : 42414604

DOI : 10.1038/s41375-026-03036-8

Keywords

Humans; Lymphoma, Mantle-Cell/pathology/diagnosis/drug therapy; Prognosis; Eosine Yellowish-(YS); Hematoxylin; Artificial Intelligence; Female;